← Back to feed

TheraCryf Plc

TCF · AIM · Health Care · mcap £4.0m today

All announcements

All RNS · 28 Key events · 18

02 Oct 26

Australian partner to progress Ox-1 Phase 1 trial

Australian partner appointed to progress Ox-1 towards Phase 1 trial
RNS 9803056 ↗
30 Sep 26

Posting of Annual Report and Notice of AGM
RNS 9797737 ↗
28 Sep 26

Final Results

Final Results for the year ended 31 March 2026
RNS 9792613 ↗
14 Sep 26

Notice of Results and Investor Presentation
RNS 9769131 ↗
11 Sep 26

Holding(s) in Company
RNS 9768777 ↗
10 Sep 26

Holding(s) in Company
RNS 9766016 ↗
07 Sep 26

Result of General Meeting
RNS 9759124 ↗
20 Aug 26

Proposed Placing & Subscription to raise £1.05m

Proposed Placing and Subscription to raise £1.05 million
RNS 9732839 ↗
24 Jun 26

Holding(s) in Company
RNS 9635147 ↗
26 May 26

Holding(s) in Company
RNS 9586109 ↗
15 May 26

Holding(s) in Company
RNS 9571303 ↗
15 May 26

Holding(s) in Company
RNS 9569683 ↗
14 May 26

Positive Ox-1 tox data in addiction programme

Positive top line data from first toxicology species in lead Ox-1 addiction programme
RNS 9567507 ↗
21 Apr 26

Investor Webinar

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor...
RNS 9529336 ↗
20 Apr 26

Successful GMP Manufacture Advances Ox-1 to Clinic

Lead Asset Ox-1 Advances Towards Clinic With Successful GMP Manufacture For Human Use
RNS 9526926 ↗
16 Apr 26

New Manufacturing Process Patent for Ox-1

New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1
RNS 9522416 ↗
14 Apr 26

Non-Binding Proposal to Acquire TheraCryf’s Assets

Non-Binding Indicative Proposal to Acquire TheraCryf's Lead Neuropsychiatry Assets Received
RNS 9517942 ↗
23 Mar 26

Ox-1 Programme Advances to Final Toxicology Study

Lead Ox-1 Programme Advances to Final Toxicology Studies Before Human Phase 1 Clinical Study
RNS 9485558 ↗
26 Jan 26

Ox-1 Addiction Programme Update

Best-in-class Ox-1 asset continues to be de-risked ahead of clinical readiness
RNS 9385540 ↗
05 Jan 26

Key Ox-1 milestone & notice of investor webinar

Ox-1 addiction programme advances closer to clinical readiness on achievement of key milestone
RNS 9332339 ↗
18 Dec 25

Potential of Preclinical Program in Mental Fatigue

· Chronic fatigue treatment market worth US$1.2 billion in 2024, rising to c.US$2.3bn by 20331
RNS 9305037 ↗
03 Dec 25

Half-year Results

Class-leading addiction programme on target to be clinic ready in 2026
RNS 9271803 ↗
26 Nov 25

Marking Addiction Awareness Week

Alderley Park, 26 November 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, is supporting Addiction Awareness Week.
RNS 9257305 ↗
24 Nov 25

Notice of Results
RNS 9251894 ↗
03 Nov 25

Ox-1 Programme Achieves Manufacturing Milestone

Scale up of drug quantity achieved ahead of schedule
RNS 9207509 ↗
16 Oct 25

Holding(s) in Company 30 % crossed / offer

TR-1: Standard form for notification of major holdings
RNS 9176171 ↗
16 Oct 25

Director/PDMR Shareholding Director buys30 % crossed / offer

Alderley Park, UK - 16 October 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, announces that Northern Standard Limited, a company that Non-Executive Director, Ed Wardle, has a 49 per cent interest...
RNS 9176170 ↗
10 Oct 25

World Mental Health Day & Q4 Conference Schedule

Marking World Mental Health Day and Q4 Conference Schedule Update
RNS 9162330 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.